

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

GID-MT554 KardiaMobile for detecting atrial fibrillation

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Yes. The committee considered that some people with comorbidities may not be suitable for KardiaMobile ECG recorder. The committee concluded that healthcare professionals should assess individuals and indications when considering whether to KardiaMobile. The committee considerations surrounding this equality consideration can be found in section 4.6 of the draft guidance.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No further equality issues were highlighted in the sponsor's submission or patient organisation questionnaires.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No further equality issues have been highlighted by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

The committee considerations surrounding this equality consideration can be found in section 4.6 of the draft guidance.

Approved by Associate Director: Anastasia Chalkidou

Date: 6th July 2021

Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional equality issues were raised during the consultation. The clinical experts highlighted that people are not able to use the device if they do not have a compatible smart device to access the KardiaMobile app. The device may also not be suitable for people who cannot remain still or have problems holding the device, however, alternative devices are available in these cases. These are described in section 4.7 of the medical technologies guidance document.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations have changed after consultation, but the changes are not expected to affect access to the technology.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations have changed after consultation, but the changes are not expected to have an adverse impact on people with disabilities. Alternative devices are available for people with disabilities who cannot remain still or have problems holding the device.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in

questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have changed after consultation but the changes are not expected to affect access or have an adverse impact, therefore, no further amends were made.

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

These are described in section 4.7 of the medical technologies guidance.

Approved by Programme Director: Sarah Byron

Date: 3 November 2021